https://www.cerevance.com https://www.cerevance.com/about https://www.cerevance.com/careers https://www.cerevance.com/contact-cerevance https://www.cerevance.com/studies/cvn424 https://www.cerevance.com/studies/cvn766 https://www.cerevance.com/job-application https://www.cerevance.com/job-submit-success https://www.cerevance.com/media https://www.cerevance.com/netsseq https://www.cerevance.com/pipeline https://www.cerevance.com/privacy-policy https://www.cerevance.com/rte-media-body https://www.cerevance.com/rte-whitebg-dktxt https://www.cerevance.com/terms-of-use https://www.cerevance.com/netsseq-test https://www.cerevance.com/studies/cvn293 https://www.cerevance.com/media/a-new-era-in-parkinsons-solengepras-leads-the-shift-beyond-dopamine https://www.cerevance.com/media/cerevance-achieves-first-milestone-in-research-collaboration-with-merck https://www.cerevance.com/media/cerevance-achieves-key-endpoints-in-phase-1-clinical-trial-of-novel-parkinsons-disease-drug-cvn424 https://www.cerevance.com/media/cerevance-achieves-second-milestone-in-research-collaboration-with-merck https://www.cerevance.com/media/cerevance-adds-47-million-in-series-b-1-extension-to-advance-robust-clinical-pipeline https://www.cerevance.com/media/cerevance-announces-first-in-human-dosing-of-cvn424-for-the-treatment-of-parkinsons-disease https://www.cerevance.com/media/cerevance-announces-leadership-transition-to-implement-next-phase-of-growth-in-advancing-novel-therapeutics-for-brain-diseases https://www.cerevance.com/media/cerevance-announces-positive-topline-data-from-phase-1-clinical-trial-of-cvn766-for-the-potential-use-in-the-treatment-of-schizophrenia https://www.cerevance.com/media/cerevance-announces-presentation-at-ad-pd-tm-2024-international-conference https://www.cerevance.com/media/cerevance-announces-presentation-at-alzheimers-research-uk-conference https://www.cerevance.com/media/cerevance-announces-presentation-at-the-34th-international-symposium-on-als-mnd https://www.cerevance.com/media/cerevance-announces-presentation-at-the-36th-european-college-of-neuropsychopharmacology-congress https://www.cerevance.com/media/cerevance-announces-presentation-at-the-sfn-neuroscience-2023-annual-meeting https://www.cerevance.com/media/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025 https://www.cerevance.com/media/cerevance-announces-publication-in-organic-process-research-and-development https://www.cerevance.com/media/cerevance-announces-publication-of-cvn766-in-bioorganic-medicinal-chemistry-letters-3 https://www.cerevance.com/media/cerevance-announces-publication-of-positive-phase-2-results-of-solengepras-for-the-treatment-of-parkinsons-disease-in-eclinical-medicine https://www.cerevance.com/media/cerevance-appoints-carrie-ann-cook-as-chief-business-officer https://www.cerevance.com/media/cerevance-appoints-clinical-development-veteran-dr-aoife-brennan-to-board-of-directors https://www.cerevance.com/media/cerevance-appoints-cns-drug-developer-james-summers-ph-d-as-scientific-advisor https://www.cerevance.com/media/cerevance-appoints-david-h-margolin-md-phd-as-senior-vice-president-of-clinical-and-translational-medicine https://www.cerevance.com/media/cerevance-appoints-david-lubner-to-board-of-directors https://www.cerevance.com/media/cerevance-appoints-industry-veteran-roland-burli-ph-d-as-vice-president-of-drug-discovery https://www.cerevance.com/media/cerevance-appoints-naidong-ye-ph-d-as-vice-president-and-head-of-chemistry-manufacturing-and-controls https://www.cerevance.com/media/cerevance-appoints-sagar-vaidya-m-d-ph-d-as-chief-medical-officer https://www.cerevance.com/media/cerevance-appoints-ted-hibben-as-chief-business-officer https://www.cerevance.com/media/cerevance-closes-45-million-series-b-financing https://www.cerevance.com/media/cerevance-doses-first-patient-in-ascend-phase-2-clinical-study-of-cvn424-a-first-in-class-non-dopaminergic-therapy-for-the-treatment-of-parkinsons-disease https://www.cerevance.com/media/cerevance-doses-first-patient-in-pivotal-phase-3-arise-trial-of-solengepras-for-treatment-of-parkinsons-disease https://www.cerevance.com/media/cerevance-doses-first-subject-in-phase-1-clinical-study-of-cvn293-a-selective-inhibitor-of-kcnk13-designed-to-selectively-modulate-neuroinflammation-for-the-treatment-of-als-and-alzheimers-disease https://www.cerevance.com/media/cerevance-doses-first-subjects-in-phase-1-clinical-trial-of-cvn766 https://www.cerevance.com/media/cerevance-enters-research-collaboration-with-takeda-to-advance-new-treatments-for-gastrointestinal-disorders https://www.cerevance.com/media/cerevance-establishes-strategic-research-collaboration-with-merck-for-the-discovery-of-novel-targets-in-alzheimers-disease https://www.cerevance.com/media/cerevance-expands-series-b-financing-to-65-million https://www.cerevance.com/media/cerevance-expands-series-b-financing-with-additional-51-million https://www.cerevance.com/media/cerevance-initiates-phase-2-trial-of-cvn424-for-parkinsons-disease https://www.cerevance.com/media/cerevance-kicks-off-2018-with-additional-10-million-of-infusions https://www.cerevance.com/media/cerevance-launched-with-new-technology-drug-portfolio-and-36m-in-cash-to-tackle-brain-diseases https://www.cerevance.com/media/cerevance-licenses-human-brain-tissue-profiling-technology-from-the-rockefeller-university https://www.cerevance.com/media/cerevance-presents-at-35th-symposium-on-medicinal-chemistry-in-eastern-england https://www.cerevance.com/media/cerevance-presents-at-iaprd-xxix-world-congress-on-parkinsons-disease-and-related-disorders https://www.cerevance.com/media/cerevance-presents-at-the-federation-of-european-neuroscience-societies-fens-forum-2024 https://www.cerevance.com/media/cerevance-presents-positive-results-from-phase-1-study-of-cvn293-at-american-academy-of-neurology-2025-annual-meeting https://www.cerevance.com/media/cerevance-presents-topline-results-from-phase-2-ascend-trial-of-solengepras-as-monotherapy-treatment-for-early-stage-parkinsons-disease-at-ad-pd-2025 https://www.cerevance.com/media/cerevance-publishes-cvn293-in-acs-medicinal-chemistry-letters https://www.cerevance.com/media/cerevance-reports-positive-phase-2-clinical-trial-results-with-cvn424-a-parkinsons-disease-drug-working-through-a-new-mechanism https://www.cerevance.com/media/cerevance-showcases-positive-phase-2-results-demonstrating-significant-reduction-in-off-time-with-solengepras-as-an-adjunctive-treatment-in-parkinsons-disease https://www.cerevance.com/media/cerevance-to-highlight-potential-of-solengepras-in-parkinsons-disease-at-the-2025-parkinson-study-group-annual-meeting https://www.cerevance.com/media/cerevance-to-participate-at-the-2023-life-sciences-private-company-showcase https://www.cerevance.com/media/cerevance-to-participate-at-the-23rd-annual-needham-virtual-health-care-conference https://www.cerevance.com/media/cerevance-to-participate-at-the-3rd-annual-needham-biotech-private-company-forum https://www.cerevance.com/media/cerevance-to-participate-at-the-leerink-biopharma-private-company-connect https://www.cerevance.com/media/cerevance-to-participate-at-the-svb-global-biopharma-conference https://www.cerevance.com/media/cerevance-to-participate-at-the-td-cowen-44th-annual-health-care-conference https://www.cerevance.com/media/cerevance-to-participate-at-the-wells-fargo-2023-private-biotech-symposium https://www.cerevance.com/media/cerevance-to-participate-at-wells-fargo-virtual-private-biotech-symposium https://www.cerevance.com/media/cerevance-to-participate-in-a-panel-discussion-at-fierce-biotech-summit-2024 https://www.cerevance.com/media/cerevance-to-participate-in-chief-medical-officer-summit-360 https://www.cerevance.com/media/cerevance-to-participate-in-fireside-chat-at-the-2023-rbc-capital-markets-healthcare-private-company-virtual-conference https://www.cerevance.com/media/cerevance-to-participate-in-panel-discussion-during-the-2022-bio-international-convention https://www.cerevance.com/media/cerevance-to-participate-in-piper-sandler-virtual-cns-symposium https://www.cerevance.com/media/cerevance-to-participate-in-precision-neurotherapeutics-panel-during-the-2024-bio-international-convention https://www.cerevance.com/media/cerevance-to-participate-in-rbc-capital-markets-2025-healthcareprivate-company-conference https://www.cerevance.com/media/cerevance-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference https://www.cerevance.com/media/cerevance-to-participate-in-the-td-cowen-46th-annual-health-care-conference https://www.cerevance.com/media/cerevance-to-participate-in-the-td-cowen-treatment-advancements-in-obesity-and-related-disorders-summit https://www.cerevance.com/media/cerevance-to-participate-in-the-truist-securities-biopharma-symposium https://www.cerevance.com/media/cerevance-to-present-at-ad-pd-tm-2023-international-conference https://www.cerevance.com/media/cerevance-to-present-at-neurodegeneration-new-biology-guiding-the-next-generation-of-therapeutic-development https://www.cerevance.com/media/cerevance-to-present-at-rbc-capital-markets-2024-global-healthcare-conference https://www.cerevance.com/media/cerevance-to-present-at-the-2023-rbc-capital-markets-global-healthcare-conference https://www.cerevance.com/media/cerevance-to-present-at-the-22nd-society-of-chemical-industry-royal-society-of-chemistry-medicinal-chemistry-symposium https://www.cerevance.com/media/cerevance-to-present-at-the-alzheimers-association-international-conference https://www.cerevance.com/media/cerevance-to-present-at-the-alzheimers-research-uk-conference-2023 https://www.cerevance.com/media/cerevance-to-present-at-the-gordon-research-conference-amyotrophic-lateral-sclerosis-and-related-motor-neuron-diseases https://www.cerevance.com/media/cerevance-to-present-at-the-needham-healthcare-conference https://www.cerevance.com/media/cerevance-to-present-at-the-rbc-capital-markets-virtual-healthcare-private-company-conference https://www.cerevance.com/media/cerevance-to-present-at-the-xvi-european-meeting-on-glial-cells-in-health-and-disease- https://www.cerevance.com/media/cerevance-to-present-at-two-medicinal-chemistry-conferences https://www.cerevance.com/media/cerevance-to-present-during-the-5th-annual-lsx-world-congress-usa https://www.cerevance.com/media/cerevance-to-present-during-the-6th-annual-lsx-world-congress-usa https://www.cerevance.com/media/cerevance-to-present-phase-2-data-on-solengepras-in-parkinsons-disease-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders https://www.cerevance.com/media/cerevance-to-present-phase-2-trial-results-on-off-time-and-sleep-related-outcomes-with-solengepras-in-parkinsons-disease-at-ad-pd-tm-2026 https://www.cerevance.com/media/cerevance-to-present-positive-phase-2-solengepras-data-in-parkinsons-disease-at-the-american-academy-of-neurology-2026-annual-meeting https://www.cerevance.com/media/cerevance-to-present-preclinical-data-during-the-cold-spring-harbor-laboratory-cshl-neurodegenerative-diseases-biology-and-therapeutics-conference-and-publication-in-neuropharmacology https://www.cerevance.com/media/cerevances-cvn058-achieves-primary-endpoint-in-phase-1b-schizophrenia-cognition-study https://www.cerevance.com/media/cerevances-cvn293-demonstrated-positive-phase-1-results-in-healthy-volunteers https://www.cerevance.com/media/dementia-discovery-fund-to-invest-5m-in-cerevance-to-seek-new-treatments-for-dementia https://www.cerevance.com/media/fierce-biotech-names-cerevance-a-fierce-15-biotech-company-of-2023 https://www.cerevance.com/media/harvards-rudolph-tanzi-phd-a-leader-in-alzheimers-disease-genetics-joins-cerevances-advisory-board https://www.cerevance.com/media/industry-central-nervous-system-specialist-lee-dawson-phd-joins-cerevance-as-vp-of-neuroscience https://www.cerevance.com/media/neuroscience-drug-development-veteran-mike-poole-m-d-facp-to-join-cerevance-board-of-directors https://www.cerevance.com/media/new-data-to-be-presented-at-upcoming-congresses-showcase-cerevances-advanced-clinical-program-in-parkinsons-disease-and-deep-pipeline-for-cns-based-disorders https://www.cerevance.com/media/oral-presentation-of-phase-1-data-on-cvn766-at-american-society-of-clinical-psychopharmacology-ascp https://www.cerevance.com/media/poster-presentation-at-the-bna-international-festival-of-neuroscience https://www.cerevance.com/media/sarah-sheikh-joins-cerevances-board-of-directors https://www.cerevance.com/media/stanford-neuroscientist-robert-malenka-to-advise-cerevance https://www.cerevance.com/media/trailblazer-in-molecular-genetics-and-neuroscience-jeremy-nathans-m-d-ph-d-to-advise-cerevance